|

RMC-6236 Clinical Trials

6 actively recruiting trials across 6 locations

Pipeline

Phase 1: 2Phase 1/2: 4

Top Sponsors

  • Revolution Medicines, Inc.4
  • Tango Therapeutics, Inc.1
  • Amgen1

Indications

  • Cancer6
  • Lung Cancer4
  • Non-small Cell Lung Cancer (NSCLC)3
  • PDAC2
  • Pancreatic Ductal Adenocarcinoma (PDAC)2

Chandler, Arizona1 trial

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Ironwood Cancer and Research Centers

Phase 1/2

Gilbert, Arizona1 trial

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Banner MD Anderson Cancer Center

Phase 1/2

Scottsdale, Arizona1 trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Mayo Clinic Scottsdale

Phase 1/2

Bakersfield, California1 trial

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Comprehensive Blood and Cancer Center

Phase 1

Orange, California1 trial

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

UC Irvine/Chao Family Comprehensive Cancer Center

Phase 1/2

Sacramento, California1 trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

University of California, Davis Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.